Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate

Contraception

Volumn 74, Issue 3, 2006, Pages 239-244

  Terlinden, Rolf ^a   Uragg, Heinz ^a   Göhler, Karin ^a   Kneip, Christa ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Chlormadinone acetate; Ethinylestradiol; Pharmacokinetics

Indexed keywords

CHLORMADINONE ACETATE; ETHINYLESTRADIOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DYSMENORRHEA; FECES ANALYSIS; FEMALE; GAS CHROMATOGRAPHY; HORMONE ACTION; HUMAN; LIQUID SCINTILLATION COUNTING; MASS SPECTROMETRY; MASTALGIA; MENSTRUAL CYCLE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION; VAGINA DISCHARGE;

ADOLESCENT; ADULT; CARBON RADIOISOTOPES; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, SYNTHETIC; ETHINYL ESTRADIOL; FECES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOTOPE LABELING; KIDNEY; KINETICS;

EID: 33746837003     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.03.011     Document Type: Article

References (31)

1. Fraser I.S. Forty years of combined oral contraception: the evolution of a revolution. Med J Aust 173 (2000) 541-544
2. Prentice R.L., and Thomas D.B. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 49 (1987) 285-401
3. Gillum L.A., Mamidipudi S.K., and Johnston S.C. Ischemic stroke risk with oral contraceptives. A meta-analysis. JAMA 284 (2000) 72-78
4. Schildkraut J.M., Calingaert B., Marchbanks P.A., Moorman P.G., and Rodriguez G.C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94 (2002) 32-38
5. Grabrick D.M., Hartmann L.C., Cerhan J.R., et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284 (2000) 1791-1798
6. Zahradnik H.P., Goldberg J., and Andreas J.O. Efficacy and safety of the new antiandrogenic oral contraceptive Belara®. Contraception 57 (1998) 103-109
7. Curran M.P., and Wagstaff A.J. Ethinylestradiol/chlormadinone acetate. Drugs 64 (2004) 751-760
8. Raudrant D., and Rabe T. Progestogens with antiandrogenic properties. Drugs 63 (2003) 463-492
9. Worret I., Arp W., Zahradnik H.P., and Andreas J.O. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 203 (2001) 38-44
10. Dibbelt L., Knuppen R., Jütting G., Heimann S., Klipping C.O., and Parikka-Olexik H. Group comparison of serum ethynylestradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months. Contraception 43 (1991) 1-21
11. Kuhnz W., Staks T., and Jütting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraception 48 (1993) 557-575
12. 2]-ethinylestradiol in young women. Eur J Clin Pharmacol 50 (1996) 231-235
13. Hümpel M., Nieuweboer B., Wendt H., and Speck U. Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception 19 (1979) 421-432
14. Goldzieher J.W. Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gynecol 160 (1989) 1260-1264
15. Orme M., Back D.J., Ward S., and Green S. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. Contraception 43 (1991) 305-316
16. Ouellet D., Hsu A., Qian J., et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 46 (1998) 111-116
17. Dugwekar Y.G., Narula R.K., and Laumas K.R. Disappearance of 1α-3H-chlormadinone acetate from the plasma of women. Contraception 7 (1973) 27-45
18. Chassard D., Legallicier P., and Dib M. Etude de la biodisponibilité relative de deux formulatins orales d'acétate de chlormadinone: Lutéran® 5 mg et Lutéran® comprimé dosé à 10 mg. Therapie 58 (2003) 127-131
19. Gibaldi M., and Perrier D. Drugs and pharmaceutical sciences. In: Swarbrick J. (Ed). Pharmacokinetics vol. 15 (1982), Marcel Dekker, Inc, New York 445-449
20. Meier J., Rettig H., and Hess H. Biopharmazie. Theorie und Praxis der Pharmakokinetik (1981), Georg Thieme Verlag, Stuttgard 383
21. Rowland M., and Tozer T.N. Clinical pharmacokinetics (1995), Lea and Febiger, Philadelphia
22. Gibaldi M., and Perrier D. In: Swarbrick J. (Ed). Drugs and pharmaceutical sciences. Pharmacokinetics vol. 15 (1982), Marcel Dekker, Inc., New York 409-415
23. Drexler G. The dosimetric quantities in the new ICRP recommendations. Radiat Prot Dosimetry 43 (1992) 93-98
24. Schröder F.H., and Radlmeier A. Steroidal antiandrogens. In: Jordan V.C., and Furr B.J.A. (Eds). Hormone therapy in breast and prostate cancer (2002), Humana Press, Totowa (NJ) 325-345
25. Stanzyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 3 (2002) 211-224
26. Newburger J., and Goldzieher J.W. Pharmacokinetics of ethinyl estradiol: a current view. Contraception 32 (1985) 33-44
27. Goldzieher J.W., and Brody S.H. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol 163 (1990) 2114-2119
28. Blode H., Wuttke W., Loock W., Röll G., and Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 5 (2000) 256-264
29. Heuner A., Kuhnz W., Heger-Mahn D., Richert K., and Hümpel M. A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. Adv Contracept 11 (1995) 207-225
30. Jung-Hoffmann C., and Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception 40 (1989) 299-312
31. Endrikat J., Blode H., Gerlinger C., Rosenbaum P., and Kuhnz W. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel. Eur J Contracept Reprod Health Care 7 (2002) 79-90